The physiologic development of fetuin-a serum concentrations in children
Martin Häusler1, Cora Schäfer, Claudia Osterwinter
1Department of Pediatrics, RWTH Aachen University Hospital, Pauwelsstrasse 30, Aachen 52074, Germany. haeusler@rwth-aachen.de
Pediatric Research
|August 20, 2009
Summary
Serum fetuin-A levels are highest in preterm infants and decrease with biological age, not chronological age. This protein
Area of Science:
- Biochemistry
- Pediatrics
- Nephrology
Background:
- Fetuin-A inhibits tissue calcification by binding calcium and phosphate.
- Pathological fetuin-A depletion is noted in children with kidney disease.
- Physiological, age-related changes in serum fetuin-A are not well understood.
Purpose of the Study:
- To prospectively evaluate age-related changes in serum fetuin-A levels in infants and children.
- To investigate the relationship between fetuin-A levels and biological vs. chronological age.
- To explore the impact of infections on fetuin-A concentrations.
Main Methods:
- Prospective evaluation of serum fetuin-A in 133 infants and children.
- Analysis of fetuin-A levels across different gestational ages and post-natal development.
- Correlation of fetuin-A levels with biological and chronological age, and intercurrent infections.
Main Results:
- Highest serum fetuin-A levels were observed between 23-30 weeks of gestation (1 ± 0.33 mg/mL).
- Fetuin-A levels decreased significantly after 30 weeks gestation, stabilizing by adolescence (0.58 ± 0.12 mg/mL).
- Decreases in fetuin-A were linked to biological age and transiently reduced by infections.
Conclusions:
- Fetuin-A plays a significant physiological role in fetal and preterm infants due to extensive tissue formation.
- Age-related changes in fetuin-A are primarily driven by biological maturation.
- Potential implications for understanding organ damage mechanisms in preterm infants, similar to children on dialysis.
More Related Videos
08:45Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...